Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 186.38B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 11.49 |
| Forward PE | 9.85 |
| Dividend | 2.91 (3.92%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,180 |
| Average Volume | 688 |
| Open | 74.20 |
| Previous Close | 74.20 |
| Day's Range | 74.20 - 74.20 |
| 52-Week Range | 65.50 - 99.50 |
| Beta | n/a |
| RSI | 53.39 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck (MRK) Reports Positive Phase 3 Trial Results on Cholesterol Reduction
Merck (MRK) Reports Positive Phase 3 Trial Results on Cholesterol Reduction
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment wi...
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.
Merck (MRK) Unveils Promising CORALreef Lipids Trial Results
Merck (MRK) Unveils Promising CORALreef Lipids Trial Results
Merck's Enlicitide Shows Promising Results In Phase 3 CORALreef Lipids Trial
(RTTNews) - Merck & Co Inc. (MRK) has unveiled the first results from its pivotal Phase 3 CORALreef Lipids trial, highlighting the efficacy of enlicitide decanoate, an investigational once-daily oral ...
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial.
Merck & Co. (MRK) Tops Dividend Stock List Amid Market Selloff
Merck & Co. (MRK) Tops Dividend Stock List Amid Market Selloff
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Powers: Concentration risk is the biggest risk in the market
Matt Powers, Managing Partner at Powers Advisory Group, warns of market concentration risk, says sentiment fatigue is hitting AI stocks, and favors quality names like Merck for their strong divid
As Merck Stock Gets Back To Its Feet, Here's One Possible Option Trade
For traders with a neutral-to-slightly bullish outlook on Merck, a cash-secured put is one way to buy the stock at a discount.
Noteworthy ETF Outflows: XLV, ABT, MRK, TMO
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have de...
Insider Sell: David Williams Sells 8,614 Shares of Merck & Co Inc (MRK)
Insider Sell: David Williams Sells 8,614 Shares of Merck & Co Inc (MRK)
Why Merck Is Sinking This Week
Investors were unimpressed with Merck's Q3 financial results.
Dow Movers: BA, MRK
In early trading on Tuesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.0%. Year to date, Merck has lost about 16.2% of its valu...
Merck (MRK) Secures $700M from Blackstone for Cancer Therapy Development
Merck (MRK) Secures $700M from Blackstone for Cancer Therapy Development
4 stocks to watch on Tuesday: SBUX, UBER, PFE, MRK
SBUX, UBER, PFE, MRK are the stocks to watch on Tuesday
Merck to receive $700M from Blackstone to develop cancer therapy
Merck (MRK) to Take Over Full Development of MK-8690
Merck (MRK) to Take Over Full Development of MK-8690
Blackstone (BX) Invests in Merck's Cancer Treatment Development
Blackstone (BX) Invests in Merck's Cancer Treatment Development
Merck Signs A Deal To Assume Full Development And Commercialization Rights To MK-8690
(RTTNews) - Merck & Co., Inc. (MRK), Tuesday announced an agreement with Dr. Falk Pharma GmbH to discontinue an existing co-development contract with the company's subsidiary Prometheus BioSciences.
Merck To Receive $700 Mln From Blackstone To Support Development Of Cancer Drug Sac-TMT
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday announced that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for the development of sacituzumab tirumotecan (sac-TM...
Merck and Blackstone enter research agreement to develop cancer therapy for $700 million
Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 million to develop an experimental cancer therapy.
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Black...
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma ...